hVISA/VISA: diagnostic and therapeutic problems.

Vancomycin is considered the goldstandard treatment for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In recent years, reduced susceptibility of S. aureus to vancomycin has emerged. This problem seems to be based on the increased use of vancomycin, with characteristic poor tissue penetration, slow bactericidal activity and risk of nephrotoxicity resulting lack of elimination of MRSA from the patient [1].